Puma Biotechnology Inc  

(Public, NASDAQ:PBYI)   Watch this stock  
Find more results for PBYI
-4.05 (-10.56%)
After Hours: 34.30 0.00 (0.00%)
Feb 22, 7:55PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.25 - 38.50
52 week 19.74 - 73.27
Open 38.05
Vol / Avg. 904,794.00/719,748.00
Mkt cap 1.20B
P/E     -
Div/yield     -
EPS -8.16
Shares 36.82M
Beta 0.40
Inst. own 97%
Feb 27, 2017
Q4 2016 Puma Biotechnology Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 10, 2017
Puma Biotechnology Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -173.06% -118.87%
Return on average equity -241.81% -148.14%
Employees 156 -
CDP Score - -


10880 Wilshire Blvd Ste 2150
LOS ANGELES, CA 90024-4106
United States - Map
+1-424-2486500 (Phone)
+1-424-2486501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

Officers and directors

Alan H. Auerbach Chairman of the Board, President, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Charles R. Eyler Senior Vice President - Finance and Administration, Treasurer
Age: 68
Bio & Compensation  - Reuters
Richard P. Bryce Senior Vice President - Clinical Research and Development.
Age: 58
Bio & Compensation  - Reuters
Steven Lo Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Richard Benton Phillips Ph.D. Interim Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance
Age: 62
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 62
Bio & Compensation  - Reuters
Adrian M. Senderowicz M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Troy E. Wilson Ph.D. J.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Frank E. Zavrl Independent Director
Age: 46
Bio & Compensation  - Reuters